Exploratory biomarker analyses of the COMBI-AD clinical trial [70,71] concluded that individuals with low TMB and high IFN-γ tumors experienced the most significant advantage with dabrafenib plus trametinib compared to the placebo. The gene discussed is IFNG; the disease is Alzheimer disease.